Merino, Jose G. MD, MPhil
doi : 10.1212/WNL.0000000000012742
Volume 97(17), 26 October 2021, p 797-798
Tobin, W. Oliver MB, BCh, BAO, PhD
doi : 10.1212/WNL.0000000000012738
Volume 97(17), 26 October 2021, p 799-800
Mead, Simon PhD
doi : 10.1212/WNL.0000000000012739
Volume 97(17), 26 October 2021, p 801-802
Tintore, Mar MD, PhD*; Cobo-Calvo, Alvaro MD, PhD*; Carbonell, Pere MStat; Arrambide, Georgina MD, PhD; Otero-Romero, Susana MD, PhD; Rio, Jordi MD, PhD; Tur, Carmen MD, PhD; Comabella, Manuel MD, PhD; Nos, Carlos MD; Arevalo, Maria Jesus PsyD; Midaglia, Luciana MD; Galan, Ingrid MD; Vidal-Jordana, Angela MD, PhD; Castillo, Joaquin MD, PhD; Rodriguez-Acevedo, Breogan MD; Zabalza de Torres, Ana MD; Salerno, Annalaura MD; Auger, Cristina MD; Sastre-Garriga, Jaume MD, PhD; Rovira, Alex MD, PhD; Montalban, Xavier MD, PhD
doi : 10.1212/WNL.0000000000012726
Volume 97(17), 26 October 2021, p e1641-e1652
To explore whether time to diagnosis, time to treatment initiation, and age to reach disability milestones have changed in patients with clinically isolated syndrome (CIS) according to different multiple sclerosis (MS) diagnostic criteria periods.
Barenie, Rachel PharmD, JD, MPH; Darrow, Jonathan SJD, JD, MBA; Avorn, Jerry MD; Kesselheim, Aaron S. MD, JD, MPH
doi : 10.1212/WNL.0000000000012730
Volume 97(17), 26 October 2021, p e1653-e1660
Pregabalin (Lyrica), a widely used drug that has generated billions in revenue as a treatment for diabetic neuropathy and other conditions, was originally discovered in an academic medical center, largely supported by public funding. We aimed to define the extent of direct federal public funding that contributed to various stages of pregabalin's development prior to US Food and Drug Administration (FDA) approval.
Kaiser, Eric A. MD, PhD; McAdams, Harrison PhD; Igdalova, Aleksandra BA; Haggerty, Edda B. BA; Cucchiara, Brett L. MD; Brainard, David H. PhD; Aguirre, Geoffrey K. MD, PhD
doi : 10.1212/WNL.0000000000012734
Volume 97(17), 26 October 2021, p e1672-e1680
To quantify interictal photophobia in migraine with and without aura using reflexive eye closure as an implicit measure of light sensitivity and to assess the contribution of melanopsin and cone signals to these responses.
Leuzy, Antoine PhD; Janelidze, Shorena PhD; Mattsson-Carlgren, Niklas MD, PhD; Palmqvist, Sebastian MD, PhD; Jacobs, Dirk PhD; Cicognola, Claudia MD, PhD; Stomrud, Erik MD, PhD; Vanmechelen, Eugeen PhD; Dage, Jeffrey L. PhD; Hansson, Oskar MD, PhD
doi : 10.1212/WNL.0000000000012727
Volume 97(17), 26 October 2021, p e1681-e1694
Phosphorylated tau (p-tau) in CSF is considered an important biomarker in Alzheimer disease (AD) and has been incorporated in recent diagnostic criteria. Several variants exist, including p-tau at threonines 181 (p-tau181), 217 (p-tau217), and 231 (p-tau231). However, no studies have compared their diagnostic performance or association to [beta]-amyloid (A[beta]) and tau-PET. Understanding which p-tau variant to use remains an important yet answered question. We aimed to compare the diagnostic accuracy of p-tau181, p-tau217, and p-tau231 in CSF for AD and their association with A[beta] and tau-PET.
Li, Xuerui MSc; Song, Ruixue PhD; Qi, Xiuying PhD*; Xu, Hui PhD; Yang, Wenzhe MPH; Kivipelto, Miia MD, PhD; Bennett, David A. MD+; Xu, Weili PhD*+
doi : 10.1212/WNL.0000000000012728
Volume 97(17), 26 October 2021, p e1695-e1706
Evidence on the association of cognitive reserve (CR) with the cognitive trajectories is limited. We aimed to examine the influence of CR indicator on domain-specific cognitive trajectories taking brain pathologies into account.
Durrani, Romella PhD; Friedrich, Matthias G. MD; Schulze, Karleen M. MMath; Awadalla, Philip PhD; Balasubramanian, Kumar MSc; Black, Sandra E. MD; Broet, Philippe MD, PhD; Busseuil, David PhD; Desai, Dipika MSc; Dummer, Trevor PhD; Dick, Alexander MD; Hicks, Jason MSc; Iype, Thomas MD; Kelton, David MD; Kirpalani, Anish MD; Lear, Scott A. PhD; Leipsic, Jonathon MD; Li, Wei PhD; McCreary, Cheryl R. PhD; Moody, Alan R. MD; Noseworthy, Michael D. PhD; Parraga, Grace PhD; Poirier, Paul MD, PhD; Rangarajan, Sumathy MSc; Szczesniak, Dorota PhD; Szuba, Andrzej MD; Tardif, Jean-Claude MD; Teo, Koon MBBCH, PhD; Vena, Jennifer E. PhD; Zatonska, Katarzyna MD; Zimny, Anna MD; Lee, Douglas S. MD, PhD; Yusuf, Salim MBBS, DPhil; Anand, Sonia S. MD, PhD; Smith, Eric E. MD, MPH
doi : 10.1212/WNL.0000000000012765
Volume 97(17), 26 October 2021, p e1707-e1716
To determine whether cognitive reserve attenuates the association of vascular brain injury with cognition.
Donlevy, Gabrielle A. MND; Garnett, Sarah P. PhD; Cornett, Kayla M.D. PhD; McKay, Marnee J. PhD; Baldwin, Jennifer N. PhD; Shy, Rosemary R. MD; Yum, Sabrina W. MD; Estilow, Timothy OTR/L; Moroni, Isabella MD; Foscan, Maria PT; Pagliano, Emanuela MD; Pareyson, Davide MD; Laura, Matilde MD, PhD; Bhandari, Trupti PT; Muntoni, Francesco MD, FRCPCH, FMed; Reilly, Mary M. MD, FRCP; Finkel, Richard S. MD; Sowden, Janet E. BSc; Eichinger, Katy J. PhD; Herrmann, David N. MBBCh; Shy, Michael E. MD; Burns, Joshua PhD*; Menezes, Manoj P. MD, PhD*
doi : 10.1212/WNL.0000000000012725
Volume 97(17), 26 October 2021, p e1727-e1736
This study examined the association between body mass index (BMI) and disability in children with Charcot-Marie-Tooth disease (CMT).
Naarding, Karin J. MD; van der Holst, Menno PhD; van Zwet, Erik W. PhD; van de Velde, Nienke M. MD; de Groot, Imelda J.M. MD, PhD; Verschuuren, Jan J.G.M. MD, PhD; Kan, Hermien E. PhD*; Niks, Erik H. MD PhD*
doi : 10.1212/WNL.0000000000012724
Volume 97(17), 26 October 2021, p e1737-e1742
To study the potential of quantitative MRI (qMRI) fat fraction (FF) as a biomarker in nonambulant patients with Duchenne muscular dystrophy (DMD), we assessed the additive predictive value of elbow flexor FF to age at loss of hand-to-mouth movement.
Guerrini, Renzo MD, FAES, FRCP; Balestrini, Simona MD, PhD; Wirrell, Elaine C. MD; Walker, Matthew C. PhD, FRCP
doi : 10.1212/WNL.0000000000012744
Volume 97(17), 26 October 2021, p 817-831
A monogenic etiology can be identified in up to 40% of people with severe epilepsy. To address earlier and more appropriate treatment strategies, clinicians are required to know the implications that specific genetic causes might have on pathophysiology, natural history, comorbidities, and treatment choices. In this narrative review, we summarize concepts on the genetic epilepsies based on the underlying pathophysiologic mechanisms and present the current knowledge on treatment options based on evidence provided by controlled trials or studies with lower classification of evidence. Overall, evidence robust enough to guide antiseizure medication (ASM) choices in genetic epilepsies remains limited to the more frequent conditions for which controlled trials and observational studies have been possible. Most monogenic disorders are very rare and ASM choices for them are still based on inferences drawn from observational studies and early, often anecdotal, experiences with precision therapies. Precision medicine remains applicable to only a narrow number of patients with monogenic epilepsies and may target only part of the actual functional defects. Phenotypic heterogeneity is remarkable, and some genetic mutations activate epileptogenesis through their developmental effects, which may not be reversed postnatally. Other genes seem to have pure functional consequences on excitability, acting through either loss- or gain-of-function effects, and these may have opposite treatment implications. In addition, the functional consequences of missense mutations may be difficult to predict, making precision treatment approaches considerably more complex than estimated by deterministic interpretations. Knowledge of genetic etiologies can influence the approach to surgical treatment of focal epilepsies. Identification of germline mutations in specific genes contraindicates surgery while mutations in other genes do not. Identification, quantification, and functional characterization of specific somatic mutations before surgery using CSF liquid biopsy or after surgery in brain specimens will likely be integrated in planning surgical strategies and reintervention after a first unsuccessful surgery as initial evidence suggests that mutational load may correlate with the epileptogenic zone. Promising future directions include gene manipulation by DNA or mRNA targeting; although most are still far from clinical use, some are in early phase clinical development.
Bossart, Abigail MD; McClune, Brian DO; Barrell, Kelsey MD; Warner, Judith MD; Majersik, Jennifer Juhl MD, MS
doi : 10.1212/WNL.0000000000012325
Volume 97(17), 26 October 2021, p 835-838
Holmes, Brandon B. MD, PhD; Russ, Jeffrey B. MD, PhD; Wu, Yvonne W. MD, MPH; Gallagher, Renata C. MD, PhD; Gano, Dawn MD, MAS
doi : 10.1212/WNL.0000000000012408
Volume 97(17), 26 October 2021, p e1743-e1746
Gregory, Timothy A. MD; Taylor, Lynne P. MD
doi : 10.1212/WNL.0000000000012269
Volume 97(17), 26 October 2021, p e1747-e1748
Saft, Carsten MD; Skodda, Sabine MD; Nguyen, Huu Phuc MD; Park, Joohyun MD; Haack, Tobias B. MD
doi : 10.1212/WNL.0000000000012264
Volume 97(17), 26 October 2021, p e1749-e1750
Feng, Chaoyi MD, PhD; Chen, Qian MD, PhD; Chen, Weimin MD; Tang, Jianjun MD, PhD; Sun, Xinghuai MD, PhD; Tian, Guohong MD, PhD
doi : 10.1212/WNL.0000000000012267
Volume 97(17), 26 October 2021, p e1751-e1752
Siegler, James E. MD; Galetta, Steven MD
doi : 10.1212/WNL.0000000000012740
Volume 97(17), 26 October 2021, p 839
Chen, Huimin; Wang, Yilong
doi : 10.1212/WNL.0000000000012736
Volume 97(17), 26 October 2021, p 839-840
Perosa, Valentina; Rotta, Johanna; Schreiber, Stefanie
doi : 10.1212/WNL.0000000000012731
Volume 97(17), 26 October 2021, p 840
Lewis, Ariane MD; Galetta, Steven MD
doi : 10.1212/WNL.0000000000012735
Volume 97(17), 26 October 2021, p 840-841
Willer, Justin
doi : 10.1212/WNL.0000000000012732
Volume 97(17), 26 October 2021, p 841
Amato, Anthony
doi : 10.1212/WNL.0000000000012733
Volume 97(17), 26 October 2021, p 841-842
Appleby, Brian Stephen MD; Maddox, Ryan PhD; Schonberger, Lawrence B. MD; Cali, Ignazio PhD; Hammett, Teresa MPH; Cohen, Mark MD; Belay, Ermias MD
doi : 10.1212/WNL.0000000000012737
Volume 97(17), 26 October 2021, p 813-816
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most common form of human prion disease and typically occurs in middle to late life. sCJD in early adulthood is extremely uncommon. The purpose of this report is to raise awareness of cases of sCJD in young patients that are not associated with a genetic mutation or acquired prion disease risk factors.
Strowd, Roy E. III MD, MEd, MS, FAAN
doi : 10.1212/WNL.0000000000012743
Volume 97(17), 26 October 2021, p 832-834
van Casteren, Daphne S. MD, PhD*; Verhagen, Iris E. MD*; van der Arend, Britt W.H. MD; van Zwet, Erik W. PhD; MaassenVanDenBrink, Antoinette PhD+; Terwindt, Gisela M. MD, PhD+
doi : 10.1212/WNL.0000000000012723
Volume 97(17), 26 October 2021, p e1661-e1671
Endogenous and exogenous female sex hormones are considered important contributors to migraine pathophysiology. Previous studies have cautiously suggested that perimenstrual migraine attacks have a longer duration and are associated with higher disability compared to nonperimenstrual attacks, but they showed conflicting results on acute therapy efficacy, pain intensity, and associated symptoms. We compared perimenstrual and nonperimenstrual migraine attack characteristics and assessed premenstrual syndrome (PMS) in women with migraine.
Chang, Jun Young MD, PhD; Kim, Wook-Joo MD, PhD; Kwon, Jee Hyun MD, PhD; Lee, Ji Sung PhD; Kim, Beom Joon MD, PhD; Kim, Joon-Tae MD, PhD; Lee, Jun MD, PhD; Cha, Jae Kwan MD, PhD; Kim, Dae-Hyun MD, PhD; Cho, Yong-Jin MD, PhD; Hong, Keun-Sik MD, PhD; Lee, Soo Joo MD, PhD; Park, Jong-Moo MD, PhD; Lee, Byung-Chul MD, PhD; Oh, Mi Sun MD, PhD; Lee, Sang-Hwa MD, PhD; Kim, Chulho MD, PhD; Kim, Dong-Eog MD, PhD; Lee, Kyung Bok MD, PhD; Park, Tai Hwan MD, PhD; Choi, Jay Chol MD, PhD; Shin, Dong-Ick MD, PhD; Sohn, Sung-Il MD, PhD; Hong, Jeong-Ho MD, PhD; Bae, Hee-Joon MD, PhD; Han, Moon-Ku MD, PhD
doi : 10.1212/WNL.0000000000012729
Volume 97(17), 26 October 2021, p e1717-e1726
We evaluated the association between admission glycated hemoglobin (HbA1c) and subsequent risk of composite vascular events, including stroke, myocardial infarction (MI), and vascular death, in patients with acute ischemic stroke and diabetes.
MacGregor, E. Anne MB, BS, MSc, MD, FFSRH
doi : 10.1212/WNL.0000000000012741
Volume 97(17), 26 October 2021, p e1753-e1756
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟